<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614793</url>
  </required_header>
  <id_info>
    <org_study_id>111315</org_study_id>
    <nct_id>NCT03614793</nct_id>
  </id_info>
  <brief_title>A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves Versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome</brief_title>
  <official_title>A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves Versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic, non-neurogenic low back pain (CLBP) is a common condition that affects many
      individuals across their lives. The lumbar facet joint has been implicated as an important
      source of CLBP, with a prevalence of 15-45%. Elements of clinical history, physical
      examination, and imaging (radiographs, standard CT scan, standard MRI sequences) provide poor
      diagnostic specificity for pain of lumbar zygapophysial joint (Z-joint) origin. Thus,
      clinicians have traditionally relied upon MBN blocks to confirm or refute this diagnosis. The
      reference standard for the diagnosis of lumbar Z-joint pain is a positive response to dual
      comparative MBN blocks, which requires pain reduction of great than or equal to 80% of
      concordant duration to that expected of two different local anesthetics on independent
      occasions. Further, dual comparative MBN blocks have a high positive predictive value for
      determining the clinical outcome of lumbar MBN RFA for the treatment of lumbar Z-joint pain;
      when patients are appropriately selected using this reference standard and rigorous MBN RFA
      technique is implemented according to practice guidelines, studies demonstrate excellent
      clinical outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic, non-neurogenic low back pain (CLBP) is a common condition that affects many
      individuals across their lives. The lumbar facet joint has been implicated as an important
      source of CLBP, with a prevalence of 15-45%. Elements of clinical history, physical
      examination, and imaging (radiographs, standard CT scan, standard MRI sequences) provide poor
      diagnostic specificity for pain of lumbar zygapophysial joint (Z-joint) origin. Thus,
      clinicians have traditionally relied upon MBN blocks to confirm or refute this diagnosis. The
      reference standard for the diagnosis of lumbar Z-joint pain is a positive response to dual
      comparative MBN blocks, which requires pain reduction of great than or equal to 80% of
      concordant duration to that expected of two different local anesthetics on independent
      occasions. Further, dual comparative MBN blocks have a high positive predictive value for
      determining the clinical outcome of lumbar MBN RFA for the treatment of lumbar Z-joint pain;
      when patients are appropriately selected using this reference standard and rigorous MBN RFA
      technique is implemented according to practice guidelines, studies demonstrate excellent
      clinical outcomes.

      In additional to MBN RFA, lumbar facet joint injection of corticosteroid is another commonly
      used treatment strategy for lumbar facet joint pain related to osteoarthritis. While clinical
      outcome studies of facet joint injection with corticosteroid have generally shown only modest
      outcome improvements, this literature is generally flawed by invalid selection protocols that
      do not require dual comparative MBN blocks in order to confirm the diagnosis of pain specific
      to the lumbar facet joint(s).

      Despite the widespread use of these two techniques (lumbar MBN RFA vs. facet joint
      corticosteroid injection), the two techniques have never been compared in an
      appropriately-designed head-to-head study. The sole outcome study comparing these two
      treatment methods used an invalid selection protocol of one positive MBN block, requiring
      only 50% relief in pain and not of concordant duration with that expected by the local
      anesthetic used; in addition, a single RFA lesion was applied with a 20g conventional RFA
      electrode and fluoroscopic images were not published, so it is unclear if parallel electrode
      technique was used, as is necessary with conventional RFA. This invalid patient selection and
      RFA technique protocol is similar to that used in the Mint Trials, which has led to a broad
      call for improving such standards in research and clinical care by a multitude of experts
      representing interventional pain, spine, and radiology specialty societies. As such, an
      appropriately designed head-to-head trial in warranted.

      Furthermore, while the conventional RFA modality has been studied extensively for MBN RFA,
      minimal outcome literature on the effectiveness of C-RFA technology has been published. C-RFA
      is similar in mechanism to conventional RFA: a thermal lesion is created by applying
      radiofrequency energy through an electrode placed at a target structure. In C-RFA, a constant
      flow of ambient water is circulated through the electrode via a peristaltic pump, maintaining
      a lowered tissue temperature by creating a heat sink. By removing heat from tissues
      immediately adjacent to the electrode tip, a lower lesioning temperature is maintained,
      resulting in less tissue charring adjacent to the electrode, less tissue impedance and more
      efficient heating of target tissue. The volume of tissue heated, and the resultant thermal
      lesion size is substantially larger with C-RFA, conferring an advantage over conventional
      RFA. Further, given the spherical geometry and forward projection the C-RFA lesions beyond
      the distal end of the electrode, the RFA probe can be positioned at a range of possible
      angles and still capture the target neural structure, whereas more fastidious, parallel
      positioning is required with conventional RFA. These technical advantages increase the
      probability of successful denervation of neural pain generators that have variability in
      anatomic location, as is the case with facet syndromes in which significant osteoarthritis is
      present, which is associated with joint hypertrophy and osteophyte formation. Additionally, a
      longer lesion of the MBN may be more reliably achieved with C-RFA compared to conventional
      RFA, potentially resulted in greater treatment durability, as the recurrent of facetogenic
      pain after successful denervation is related to reinnervation by nerve re-growth to bridge
      the gap created by the lesion. Consistent with this technical advantage, there is preliminary
      evidence for superiority of C-RFA compared to both conventional RFA and other novel RFA
      techniques in the treatment of sacroiliac joint-mediated pain.

      Lumbar facet joint pain is a common and costly cause of chronic low back pain. Lumbar MBN RFA
      and facet joint injection of steroid are two commonly used treatment strategies for lumbar
      facet-mediated pain, yet the two techniques have never been compared in an
      appropriately-designed head-to-head trial. Further there is minimal clinical outcome
      literature describing the effectiveness of MBN C-RFA despite its technical advantages over
      conventional MBN RFA. We will determine if individuals with lumbar facet syndrome who are
      treated with MBN C-RFA compared to face joint injection of corticosteroid have a greater
      likelihood of experiencing meaningful relief of low back pain symptoms, functional
      improvement, and reduction of analgesic medication use at both short and long-term follow-up.
      Answering this clinical question will help determine which standard of care technique is
      superior, such that patients with lumbar facet syndrome can get be offered the best treatment
      available.

      As such, the goal of the proposed study is to determine if individuals with lumbar facet
      syndrome who are treated with C-RFA of the MBNs compared to face joint injection of
      corticosteroid have a greater likelihood of experiencing meaningful relief of low back pain
      symptoms, functional improvement, and reduction of analgesic medication use at both short and
      long-term follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the proportion of patients with a successful response to lumbar MBN C-RFA versus facet joint injection of corticosteroid.</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome for the randomized trial is the proportion of responders, defined by a reduction in NPRS score â‰¥50% at the 3-month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function (ODI and PF CAT)</measure>
    <time_frame>2 years</time_frame>
    <description>The ODI and PF CAT are two validated survey-based measures of physical function and how low back pain may affect physical function/functional disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global function (Global-10)</measure>
    <time_frame>2 year</time_frame>
    <description>The Global-10 is a validated survey-based assessment tool of global functioning that includes symptoms, function, and health care related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic use (MQS III score)</measure>
    <time_frame>2 year</time_frame>
    <description>Evaluate changes in opioid and non-opioid analgesic use in both groups, as assessed by the conversions to daily morphine equivalent use and Medication Quantification Scale III score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of change (PGIC)</measure>
    <time_frame>2 year</time_frame>
    <description>PGIC survey-based assessment of subjective improvement in overall symptoms. This scale evaluates all aspects of patients' health and assesses if there has been an improvement or decline in clinical status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 year</time_frame>
    <description>Report immediate, short-term, and long-term adverse effects, using a standardized survey that includes a comprehensive query of known adverse events associated with systemic steroid effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lumbar Facet Syndrome</condition>
  <arm_group>
    <arm_group_label>Cooled Radiofrequency Ablation Procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Facet Joint Inject Procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome</intervention_name>
    <description>Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.</description>
    <arm_group_label>Cooled Radiofrequency Ablation Procedure</arm_group_label>
    <arm_group_label>Facet Joint Inject Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients aged &gt; 40 capable of understanding and providing consent in English and
             capable of complying with the outcome instruments used.

          -  Axial (non-radicular) back pain for at least 3 months (ie Chronic Low Back Pain), with
             pain lasting at least half of the days within those 3 months, that did not respond to
             conventional treatment such as physical therapy, oral analgesic agents, and
             non-invasive adjunctive treatments. The pain can be unilateral or bilateral. The pain
             can also include referred lower limb pain.

          -  7-day worst numeric pain rating score (NPRS) for back pain of 5/10 or greater at
             baseline evaluation.

          -  Positive responses to dual comparative diagnostic MBN blocks using 0.5mL of 0.5%
             bupivacaine and 4% lidocaine, on respective encounters on separate days, at each of
             the appropriate MBNs. The blocks are administered in a double-blind fashion so that
             neither the subject nor the independent assessor is aware of the local anesthetic
             used.

        Exclusion Criteria:

          -  Focal neurologic signs or symptoms.

          -  Radiologic evidence of a symptomatic herniated disc or nerve root impingement related
             to spinal stenosis.

          -  Active systemic or local infections at the site of proposed needle and electrode
             placement.

          -  Coagulopathy or other bleeding disorder.

          -  Receipt of remuneration for their pain treatment (e.g. disability, worker's
             compensation, auto injury in litigation or pending litigation).

          -  History of prior spine surgery.

          -  Grade 2 Spondylolisthesis at an affected or adjacent level.

          -  BMI &gt;35.

          -  Incarceration.

          -  Cognitive deficit affecting ability to complete the assessment instruments.

          -  Inability to read English and complete the assessment instruments.

          -  Allergy to local anesthetics.

          -  Chronic widespread pain or somatoform disorder (e.g. fibromyalgia).

          -  Prior lumbar MBN radiofrequency neurotomy.

          -  Addictive behavior, severe clinical depression, anxiety, or any mental health
             condition with psychotic features.

          -  Possible pregnancy or other reason that precludes the use of fluoroscopy.

          -  Daily chronic opiate use of &gt;50 morphine equivalents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Zack McCormick</investigator_full_name>
    <investigator_title>Associate Professor, Spine and Pain Medicine Director, Clinical Spine Research Director, Interventional Spine and Musculoskeletal Medicine Fellowship, Division of Physical Medicine and Rehabilitation University of Utah School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

